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متالزمة تكيس املبايض املتعدد
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abstract: Objectives: This study aimed to compare endocrinologists’ versus gynaecologists’ approaches in 
using the Rotterdam criteria to diagnose polycystic ovarian syndrome (PCOS). Methods: This cross-sectional 
study was conducted at Physiology Department, King Saud University, Riyadh, Saudi Arabia, between December 
2017 and April 2018. A validated self-administered questionnaire in English was used to obtain information from 
endocrinologists and gynaecologists regarding their approaches to diagnosing PCOS. Each group’s diagnostic use 
of the Rotterdam criteria, association between years of experience and clinical decision-making, clinical features 
leading to diagnosis and considerations in the diagnosis of biochemical parameters that define hyperandrogenism 
were evaluated. Results: A total of 132 physicians were included in this study (response rate: 27%); 77 (58.3%) were 
endocrinologists and 55 (41.7%) were gynaecologists. Most of the respondents (79.5%) had ≤20 years of experience. 
A statistically significant difference was detected between the endocrinologists and gynaecologists (98.7% versus 
81.8%; P = 0.001) in their consideration of hyperandrogenism in the diagnosis. The gynaecologists relied more on 
ovarian morphology than the endocrinologists did (76.4% versus 45.5%, P <0.0001). Physicians with more experience 
used ovarian ultrasonography more compared to those with less experience (P = 0.006). Conclusion: There was 
disparity in the diagnostic approaches of endocrinologists, who rely more on androgen levels for diagnosis of PCOS 
versus gynaecologists, who more frequently use an ovarian morphology assessment. Increased years of experience 
increased the rate of ultrasonography use for PCOS diagnosis in both groups.
Keywords: Polycystic Ovary Syndrome; Gynecology; Endocrinology; Diagnosis; Hyperandrogenism; Hirsutism; 
Healthcare Disparities; Saudi Arabia.
امللخ�ص: الهدف: هدفت هذه الدرا�صة اإىل مقارنة اأ�صلوب اأطباء الغدد ال�صماء باأطباء الن�صاء والوالدة يف ا�صتخدامهم معايري روتردام عند 
ت�صخي�ض متالزمة تكي�ض املباي�ض املتعدد. الطريقة: مت عقد هذه الدرا�صة امل�صتعر�صة يف ق�صم وظائف االأع�صاء يف جامعة امللك �صعود 
يف الريا�ض-اململكة العربية ال�صعودية ما بني دي�صمرب 2017 وحتى اأبريل 2018. وقد مت عمل ا�صتبيان موزع ذاتيًا باللغة االإجنليزية جلمع 
البيانات من كال التخ�ص�صني عن طرق ت�صخي�صهم ملتالزمة تكي�ض املباي�ض املتعدد. قيمت االأ�صئلة مقدار اال�صتخدام ملعايري روتردام، 
ارتفاع  عند  الظاهرة  املختربية  والنتائج  الت�صخي�ض  يف  املوجهة  ال�رسيرية  ال�صفات  االإكلينيكية،  والقرارات  اخلربة  �صنني  بني  العالقة 
هرمونات الذكورة. النتائج: مت احل�صول على عينة من 132 طبيبًا )مقدار ا�صتجابة: %27(، منهم )%58.3( 77 اأطباء غدد �صماء و )41.7%( 55
اأطباء ن�صاء ووالدة. كان اأغلب امل�صتجيبني )%79.5( ذوي خربة 20≥ �صنة. مت اإيجاد فرق معترب اح�صائيًا بني اأطباء الغدد واأطباء الن�صاء 
والوالدة )%98.7 مقابل %81.8؛ القيمة االحتمالية P = 0.001( يف اعتمادهم على فرط االأندروجينات عند الت�صخي�ض. اعتمد اأطباء الن�صاء 
 .)P  >0.0001 %45.5، القيمة االحتمالية  )%76.4 مقابل  والوالدة ب�صورة اأكرب على مورفولوجيا املبي�ض مقارنة باأطباء الغدد ال�صماء 
.)P = 0.006 باالإ�صافة اإىل اأن االأطباء ذوي اخلربة االأطول طلبوا الت�صوير ال�صونوغرايف اأكرث مقارنة بذوي اخلربة االأقل )القيمة االحتمالية
اأطباء الغدد ال�صماء الذين يعتمدون على الهرمونات االأندروجينية، مقارنة باأطباء  اأ�صاليب الت�صخي�ض عند  اخلال�صة: هناك اختالف يف 
التخ�ص�صني  ال�صوتية يف كال  االأ�صعة  �صنوات اخلربة من معدل طلب  زاد عدد  املباي�ض.  �صكل  لتقييم  اأكرث  الذين مييلون  والوالدة  الن�صاء 
لت�صخي�ض متالزمة تكي�ض املباي�ض املتعدد.
الكلمات املفتاحية: متالزمة تكي�ض املباي�ض املتعدد؛ طب الن�صاء والوالدة ؛ طب الغدد ال�صماء؛ ت�صخي�ض؛ فرط االأندروجينات؛ زيادة ال�صعر؛ فوارق 
يف الرعاية ال�صحية؛ العربية ال�صعودية.
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Advances in Knowledge
- This study sheds light on aspects of diagnosis that might affect polycystic ovarian syndrome (PCOS) prevalence estimations and 
considerations of its impact in the Middle East.
- Certain aspects of the use of ultrasonography findings and biochemical features of PCOS require further empirical attention.
- This report is the first from the Middle East to demonstrate disparities between gynaecologists and endocrinologists in the use of 
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Polycystic ovarian syndrome (pcos), the most common endocrine disorder in women of reproductive age, presents with 
heterogeneous manifestations and a wide spectrum 
of severity.1 Among all specialty society guidelines, 
PCOS diagnosis is made when two of the following 
three criteria are met: clinical and/or biochemical 
signs of hyperandrogenism, chronic oligomenorrhea/
anovulation and morphological changes of the ovaries 
on ultrasound.2 According to these criteria, PCOS 
can be classified into four phenotypes labelled A–D. 
Patients who experience phenotypes A and B are known 
to have classic PCOS. Women with phenotype A meet 
three criteria (oligomenorrhoea, hyperandrogenism 
and polycystic ovaries [PCO]), while those with 
phenotype B feature hyperandrogenism and menstrual 
irregularities. Patients with ovulatory PCOS 
(phenotype C) have normal ovulation but elevated 
androgen levels and PCO. Non-hyperandrogenic 
PCOS (phenotype D) is the syndrome’s mildest 
form; women with this phenotype lack hormonal 
disturbances and the syndrome presents as menstrual 
irregularity with PCOS morphology.3
Associations have been made between PCOS 
and dyslipidaemia, obesity, hyperinsulinemia, and 
hyperglycaemia.4 Patients with hyperandrogenism 
experience irregular menstrual cycles, chronic 
anovulation, infertility, acne, seborrhoea and male 
pattern baldness. These distressing symptoms may 
cause psychological problems and depression and lead 
to marital and social instability.4
PCOS is a significant global public health issue 
with reproductive, metabolic and psychological 
features. Unfortunately, it is underdiagnosed 
and poorly managed, and patients often lack the 
collaborative efforts of a multidisciplinary team 
to tackle discrepancies in PCOS’s diagnosis and 
management.1 A previous study reported frustration 
among patients with PCOS due to delayed diagnosis, 
wherein 33.6% of women waited >2 years and had the 
involvement of three or more health professionals 
before diagnosis.5 A recent cross-sectional study 
using an online questionnaire found that women 
with PCOS experienced greater distrust of their 
primary care physicians’ opinions than women 
without PCOS.6 Surprisingly, a recent large-scale 
survey conducted in North America of PCOS patient 
dissatisfaction with diagnosis and treatment reported 
that a large proportion of physicians were unaware of 
the syndrome’s diagnostic criteria. The same survey 
showed differences in screening practices as well as 
discrepancies in the management of PCOS across 
specialties.7 
A recent systematic review and meta-analysis 
investigated the prevalence of PCOS among different 
ethnic groups and found variations by ethnicity and 
across different diagnostic criteria.8 This finding 
affirms the need for specific guidelines for each ethnic 
group to avoid under- or overdiagnosis. In addition, 
the study found a 16% prevalence of PCOS diagnosed 
using the Rotterdam criteria in Turkey and Iran.8 
The prevalence of PCOS in Saudi Arabia has not 
yet been determined; however, a study conducted at 
Taibah University, Medina, Saudi Arabia, reported 
that 53.7% of students with menstrual irregularities, 
acne and hirsutism had PCO.9 More importantly, it is 
unknown whether physicians of different specialties in 
Saudi Arabia consistently use the Rotterdam criteria 
to diagnose PCOS or follow different methods, which 
might lead to significant delays in diagnosis or an 
underdiagnosis of the disease. Therefore, this study 
aimed to compare the approaches of endocrinologists 
with those of gynaecologists using the Rotterdam 
criteria to diagnose PCOS and explore whether these 
differences affect the diagnostic process. Furthermore, 
this study aimed to identify the clinical features used 
to make a diagnosis with the biochemical values used 
to define hyperandrogenism.
Methods 
This cross-sectional study was conducted from 
December 2017 to April 2018 at Physiology Depart- 
ment, King Saud University, Riyadh, Saudi Arabia, and 
included endocrinologists and gynaecologists who 
encounter PCOS patients in clinical practice. 
A standardised English questionnaire from the 
European Society of Endocrinology PCOS Special 
Interest Group on the diagnosis and management of 
PCOS was used.10 The authors granted permission to 
use the questionnaire but only the section pertaining 
Rotterdam criteria to diagnose PCOS. 
Application to Patient Care
- This study highlights the importance of reinforcing the Rotterdam criteria to improve PCOS clinical outcomes and patient safety by 
decreasing diagnostic errors, preventing management delays and utilising resources properly. 
- Using the Rotterdam criteria consistently and collaborating across specialities may decrease the financial burden on health institutions 
and patients in regard to PCOS in Saudi Arabia. 
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to diagnostics was used. The questionnaire consisted 
of 16 questions that aimed to understand physicians’ 
approaches to PCOS diagnosis using the Rotterdam 
criteria. The questionnaire was self-administered 
and distributed via e-mail to endocrinologists, 
gynaecologists and members of the Saudi Society of 
Endocrinology and Metabolism. The initial response 
rate was low; hence, paper-based questionnaires were 
distributed to participants at the 5th International 
Conference of Endocrinology and Diabetes in Riyadh 
and during clinical meetings of both specialties 
at King Khalid University Hospital in Riyadh. The 
questionnaires were collected using convenience 
sampling due to time limitations. 
The sample size was estimated to be 64 physicians 
from each specialty using the two proportions formula. 
Data were analysed using Statistical Package for the 
Social Sciences (SPSS), Version 21.0 (IBM Corp., 
Armonk, New York, USA). Descriptive statistics 
(i.e. frequencies, percentages, means and standard 
deviation) were used to describe categorical and 
quantitative variables. A chi-square test was used to 
compare answers between specialties. A P value of 
≤0.05 was considered statistically significant. 
This study was approved by the Ethical 
Committee of the Institutional Review Board of the 
College of Medicine, King Saud University (E-18-
3476). All participants signed a consent form prior 
to being included in this study and it was explained 
that participation was voluntary and that they could 
withdraw from the study at any time.
Results
A total of 132 respondents were included in this 
study (response rate: 27%), of which 77 (58.3%) were 
endocrinologists and 55 (41.7%) were gynaecologists. 
In total, 87 respondents (65.9%) were consultants, 
25 (18.9%) were fellows, 16 (12.1%) were residents 
and four (3%) were registrars. A total of 117 (88.6%) 
respondents were familiar with the Rotterdam criteria. 
Most participants (79.5%) had less than 20 years of 
clinical experience [Table 1]. 
A statistically significant difference was found 
between endocrinologists and gynaecologists in the 
use of hyperandrogenism for diagnosing PCOS; almost 
all endocrinologists (98.7%) used hyperandrogenism 
always, while significantly fewer gynaecologists 
(81.8%; P = 0.001) relied on this parameter for their 
diagnoses [Table 2]. 
No significant difference was found in physicians’ 
years of experience in relation to their approach 
to the Rotterdam criteria except in their use of 
ultrasonography to determine polycystic ovarian 
Table 1: Characteristics of physicians according to spec- 
ialty at different institutions in Riyadh (N = 132)






Male 43 (55.8) 18 (32.7)
Female 34 (44.2) 37 (67.2)
Job title
Resident 0 (0) 16 (29.1)
Registrar 1 (1.3) 3 (5.4)
Fellow 16 (20.8) 9 (16.4)
Consultant 60 (77.9) 27 (49)
Experience in years
≤20 68 (88.3) 37 (67.3)
>20 9 (11.7) 18 (32.7)
Familiar with the Rotterdam criteria
Yes 70 (90.9) 47 (85.5)
No 7 (9.1) 8 (14.5)
Table 2: Comparison of approaches to polycystic ovarian syndrome diagnosis between endocrinologists and gynaecol- 
ogists at different institutions in Riyadh
Criteria used Frequency* Specialty, n(%) P value
Endocrinology (n = 77) Gynaecology (n = 55)
Hyperandrogenism (clinical/
biochemical)
Always 76 (98.7) 45 (81.8) 0.001
Sometimes or never 1 (1.3) 10 (18.2)
Oligomenorrhea/amenorrhoea Always 66 (85.7) 42 (76.4) 0.17
Sometimes or never 11 (14.3) 13 (23.6)
Polycystic ovarian morphology Always 35 (45.5) 42 (76.4) <0.0001
Sometimes or never 42 (54.5) 13 (23.6)
*The “sometimes” and “never” categories were combined due to small counts.
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morphology to diagnose PCOS (P = 0.006). In this 
area, physicians with greater experience were more 
likely to consider ovarian morphology [Table 3].
In the two specialities, the percentage of 
professionals using clinical features for diagnosing 
PCOS was comparable. Endocrinologists and 
gynaecologists reported menstrual disturbances 
(100% and 96.4%, respectively) and hirsutism (97.4% 
and 85.5%, respectively) as the main complaints 
directing physicians toward the clinical diagnosis 
of PCOS. Furthermore, most endocrinologists and 
gynaecologists considered acne (76.6% and 72.7%, 
respectively) and infertility (71.4% and 72.7%, 
respectively) as important features, while an elevated 
body mass index (BMI; 58.4% and 63.6%, respectively) 
and hair loss (50.6% and 49.1%, respectively) were the 
least considered features [Figure 1]. 
Endocrinologists investigated androgen hormone 
levels more often than gynaecologists as evidenced by 
increased orders of dehydroepiandrosterone sulfate 
(DHEAS; 75.3% versus 45.5%) and total testosterone 
(TT; 68.8% versus 47.3%) levels [Figure 2]. 
Table 3: Comparison of approaches to PCOS diagnostic criteria in relation to seniority
Criteria used Frequency* Experience in years, n (%) P value
≤20 (n = 105) >20 (n = 27)
Hyperandrogenism (Clinical/
biochemical)
Always 97 (92.4) 24 (88.9) 0.558
Sometimes or never 8 (7.6) 3 (11.1)
Oligomenorrhea/amenorrhoea Always 86 (81.9) 22 (81.5) 0.959
Sometimes or never 19 (18.1) 5 (18.5)
Polycystic ovarian morphology Always 55 (52.4) 22 (81.5) 0.006
Sometimes or never 50 (47.6) 5 (18.5)
*The “sometimes” and “never” categories were combined due to small counts.
 
Figure 1: Percentage of gynaecologists and endocrinologists using clinical features for polycystic ovarian syndrome diagnosis 
BMI = body mass index.  *P <0.01.
 
Figure 2: Percentage of gynaecologists and endocrinologists using biochemical parameters as clinical features for polycystic 
ovarian syndrome diagnosis 
AS = androstendione; FAI = free androgen index; DHEAS = dehydroepiandrosterone sulfate; TT = total testosterone; FT = free testosterone.  *P 
<0.05.  †P <0.0001.
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Discussion 
Although several international studies have compared 
approaches taken by different medical professionals to 
diagnose PCOS, to the best of the authors’ knowledge 
there are no studies examining this in the Middle 
East.1,10–12 One of the main findings of the current 
study was the disparity in the diagnostic approach to 
PCOS between endocrinologists and gynaecologists in 
Saudi Arabia. It was observed that hyperandrogenism 
coupled with oligomenorrhea/amenorrhoea 
was the key criteria guiding endocrinologists to 
a diagnosis. This finding is consistent with the 
findings of European and Australian studies in 
which endocrinologists considered androgen excess 
and menstrual disturbances as essential criteria for 
diagnosing PCOS.10,11 Conversely, less than half of 
the endocrinologists (45.5%) who participated in this 
study considered using ultrasonography to diagnose 
PCOS, which is similar to the practice of Australian 
endocrinologists.11 Almost two-thirds of European 
endocrinologists used ovarian ultrasonography to 
diagnose PCOS in collaboration with gynaecologists.10 
This finding may reflect the possibility that specialists 
typically use practice-specific diagnostic criteria 
to diagnose PCOS as was suggested by a previous 
European survey.10 
In the current study, the majority of gynaecologists 
gave each criterion—hyperandrogenism, menstrual 
irregularities and ovarian ultrasonography—equal 
importance. This finding is in contrast with Australian 
gynaecologists, who reportedly relied heavily on 
ovarian morphology to make their diagnoses, and 
German gynaecologists, who also considered PCO and 
androgen excess as the two most important criteria for 
establishing their diagnoses.11,12 This difference might 
be explained by the difference in timing between this 
study and previous studies that were conducted before 
the spread of awareness of the diagnostic criteria 
for PCOS. Another reason for this contrast may be 
differences in the teaching programmes and practices 
applied in each country. An online questionnaire-
based study recently investigated the practices of 
European, North American and other continents’ 
physicians, and found that both European physicians 
and physicians of other continents were more likely to 
use the Rotterdam criteria than American physicians.13
The current study demonstrated that physicians 
from both specialities with more years of experience 
were more likely to use ultrasonography to diagnose 
PCOS. This finding may be due to the fact that two-
thirds of participants who had more than 20 years 
of experience were gynaecologists. The international 
evidence-based guidelines recently stated that ovarian 
ultrasonography is not necessary for a PCOS diagnosis 
in the presence of irregular menstrual cycles and 
hyperandrogenism.14 Variations in the approach to 
diagnosis could lead to underdiagnosis, misdiagnosis 
or a delay in the initiation of appropriate management, 
resulting in serious yet preventable complications.15 
Currently, consistent care that considers evidence-
based guidelines across all features of PCOS is lacking, 
which indicates the need to educate physicians and 
improve the diagnosis of and holistic care for patients 
with PCOS.5
This study’s participants were asked about the 
most important clinical and biochemical features of 
PCOS. Clinically, both specialties agreed that menstrual 
disturbances and hirsutism were its two fundamental 
features, followed by acne, infertility, elevated BMI and 
hair loss. In line with the researchers’ observations, 
the European survey reported that the majority of 
their participants reported hyperandrogenism and 
menstrual disturbances when diagnosing PCOS.10 
Similar to German gynaecologists, more than 60% 
of this study’s participating gynaecologists specified 
a high BMI as an important criterion for a PCOS 
diagnosis.12 The high prevalence of obesity among 
Saudi women might be the reason that our participants 
believe that menstrual irregularities and hirsutism are 
more specific to PCOS than obesity.16 With regard to 
alopecia, it is difficult to clinically assess hair loss due 
to its subjective nature.
Furthermore, the biochemical parameters most 
commonly requested by endocrinologists were DHEAS 
and TT, while gynaecologists paid more attention to 
free testosterone (FT) in addition to TT and DHEAS. 
This finding might be due to endocrinologists usually 
managing a variety of adrenal disorders and that they 
prefer to exclude other causes of hyperandrogenism. 
As recommended by the international evidence-based 
guidelines, FT and the free androgen index should be 
used to confirm a PCOS diagnosis. If FT or TT are 
not elevated, it may be helpful to measure DHEAS 
as well as androstenedione, even though both have 
limited additional value for establishing the diagnosis 
of PCOS.14 This finding raises concerns about the 
accuracy of routine investigations and how they can 
hinder the early detection of PCOS and delay its 
management, consequently increasing complications 
and comorbidities.
Previous research has indicated that patients 
with PCOS are confused due to healthcare providers’ 
struggles to make a diagnosis with controversial 
recommendations.17 One of the most debated 
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criteria is the use of ovarian ultrasonography, which 
is more closely related to fertility than metabolic 
outcomes, and its importance is perceived differently 
among specialties according to patients’ presenting 
complaints.18 Moreover, the diurnal variation in 
testosterone levels, the effects of sex hormone-binding 
globulin on TT and the variability of assay methods all 
play a role in hindering diagnostic accuracy.19 
These findings cannot be generalised to Saudi 
Arabia’s physician population because of the study’s 
small sample size, low response rate and limited 
resources that prompted a convenience sampling 
method. However, this study is the first in the Middle 
East to address this topic and its findings may provide 
useful information to serve as a starting point for future 
PCOS studies in the region. In cases of suspected 
PCOS, it is recommended to use the new diagnostic 
guidelines; however, further studies are necessary to 
investigate the various dimensions of PCOS, such as its 
prevalence, epigenetics and management modalities. 
These recommendations should help improve the care 
of and prevent complications in patients with PCOS. 
Conclusion
Endocrinologists and gynaecologists in Saudi Arabia 
use different diagnostic approaches to PCOS. The 
current findings indicate the importance of addressing 
the health concerns of patients with PCOS and 
establishing a consistent diagnostic and management 
plan. Such plans should be discussed thoroughly with 
each patient. Furthermore, healthcare teams should 
be educated about recent guidelines for managing 
PCOS and, when appropriate, refer patients to other 
specialists for diagnosis and management. 
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